Jay Steingrub to Survival Analysis
This is a "connection" page, showing publications Jay Steingrub has written about Survival Analysis.
Connection Strength
0.162
-
White DB, Carson S, Anderson W, Steingrub J, Bird G, Curtis JR, Matthay M, Peterson M, Buddadhumaruk P, Shields AM, Ernecoff N, Shotsberger K, Weissfeld L, Chang CH, Pike F, Lo B, Hough CL. A Multicenter Study of the Causes and Consequences of Optimistic Expectations About Prognosis by Surrogate Decision-Makers in ICUs. Crit Care Med. 2019 09; 47(9):1184-1193.
Score: 0.037
-
Steingrub JS, Mundt DJ. Blood glucose and neurologic outcome with global brain ischemia. Crit Care Med. 1996 May; 24(5):802-6.
Score: 0.029
-
Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, Brower RG, Shanholtz C, Rock P, Douglas IS, deBoisblanc BP, Hough CL, Hite RD, Thompson BT. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014 Jun 05; 370(23):2191-200.
Score: 0.026
-
Rice TW, Wheeler AP, Thompson BT, deBoisblanc BP, Steingrub J, Rock P. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA. 2011 Oct 12; 306(14):1574-81.
Score: 0.021
-
Kinasewitz GT, Privalle CT, Imm A, Steingrub JS, Malcynski JT, Balk RA, DeAngelo J. Multicenter, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shock. Crit Care Med. 2008 Jul; 36(7):1999-2007.
Score: 0.017
-
L?pez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004 Jan; 32(1):21-30.
Score: 0.012
-
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 08; 344(10):699-709.
Score: 0.010
-
Abraham E, Baughman R, Fletcher E, Heard S, Lamberti J, Levy H, Nelson L, Rumbak M, Steingrub J, Taylor J, Park YC, Hynds JM, Freitag J. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med. 1999 Aug; 27(8):1478-85.
Score: 0.009